Wells Fargo
XBIO icon

Wells Fargo’s Xenetic Biosciences XBIO Stock Holding History

Wells Fargo’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$41 – 7531
2024
Q1 		$41 Hold
11
– – ﹤0.01% 6883
2023
Q4 		$38 Buy
11
+1
+10% +$4 ﹤0.01% 7002
2023
Q3 		$49 Sell
10
-1
-9% -$4 ﹤0.01% 6923
2023
Q2 		$36 Hold
11
– – ﹤0.01% 7141
2023
Q1 		$43 Buy
11
+1
+10% +$5 ﹤0.01% 7150
2022
Q4 		$29 Hold
10
– – ﹤0.01% 7187
2022
Q3 		$0 Buy
10
+1
+11% +$8 ﹤0.01% 7480
2022
Q2 		$0 Buy
9
+1
+13% +$8 ﹤0.01% 7605
2022
Q1 		$0 Hold
8
– – ﹤0.01% 7930
2021
Q4 		$0 Buy
8
+3
+60% +$48 ﹤0.01% 7896
2021
Q3 		$0 Sell
5
-1
-17% -$27 ﹤0.01% 7602
2021
Q2 		$0 Hold
6
– – ﹤0.01% 7527
2021
Q1 		$0 Buy
6
+2
+50% +$53 ﹤0.01% 7455
2020
Q4 		$0 Hold
4
– – ﹤0.01% 7096
2020
Q3 		$0 Buy
4
+1
+33% +$11 ﹤0.01% 6995
2020
Q2 		$0 Hold
3
– – ﹤0.01% 6908
2020
Q1 		$0 Buy
+3
New +$35 ﹤0.01% 6891

Other funds holding XBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo's XBIO Position: Q2 2024 in Review

Wells Fargo sold out of Xenetic Biosciences (XBIO) in Q2 2024, closing a stake of 11 shares — an estimated $41 sold.

Wells Fargo first reported a position in XBIO in Q1 2020 and held it in 17 quarters. The position peaked at $49 in Q3 2023. 5 funds tracked by Wall St. Rank hold XBIO as of Q2 2024.

  • Wells Fargo reported no remaining Xenetic Biosciences position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 11 Xenetic Biosciences shares in Q2 2024, an estimated $41.
  • Wells Fargo first reported a position in Xenetic Biosciences in Q1 2020 and held it in 17 quarters.
  • Wells Fargo's Xenetic Biosciences position peaked at $49 in Q3 2023.
  • 5 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.